Article Text

PDF

Treatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months.
  1. R Pérez,
  2. R Pravia,
  3. A Linares,
  4. M González,
  5. M Rodríguez,
  6. J L Lombraña,
  7. S Riestra,
  8. A Suárez,
  9. L Rodrigo
  1. Gastroenterology Unit, Hospital Central de Asturias, School of Medicine, Oviedo, Spain.

    Abstract

    This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment was 68.7%, an improvement over other studies, but the high rate of relapse (85% in patients who responded) suggested that a nine month treatment period was insufficient in most cases. Histological improvement was seen in more than 80% of responders to interferon, including a reduction in inflammatory activity, necrosis, and fibrosis.

    Statistics from Altmetric.com

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.